Bepirovirsen offers selected patients a chance to maintain viral control after treatment ends. Eligibility criteria and safety monitoring will shape its use.
Key Takeaways
- The FDA approved Hibsago (bepirovirsen), the first antisense oligonucleotide approved in the United States for chronic hepatitis B.
- In pooled Phase 3 trials, 19% achieved functional cure versus 0% with placebo, with both groups initially receiving background antiviral therapy.
- Treatment requires careful patient selection and monitoring for hepatic flares and thrombocytopenia. Completing Hibsago does not automatically mean stopping existing antivirals.
Data Snapshot
| Item | Details |
|---|---|
| Company | GSK; licensed from and developed with Ionis Pharmaceuticals |
| Product | Hibsago (bepirovirsen) |
| FDA approval | October 20, 2026 |
| Drug class | Antisense oligonucleotide (ASO) |
| Eligible patients | Adults without cirrhosis, on nucleos(t)ide analogue reverse transcriptase inhibitor therapy for ≥6 months, with suppressed HBV DNA and HBsAg ≤3,000 IU/mL on an FDA-authorized test |
| Administration | Subcutaneous injections for up to 24 weeks alongside existing antiviral therapy |
| Pivotal studies | Phase 3 B-Well 1 and B-Well 2 |
| Pooled functional cure rate | 19% with bepirovirsen versus 0% with placebo |
Hibsago is the product name; bepirovirsen is its active ingredient. The treatment initially supplements existing antiviral therapy.
What Happened
On October 20, 2026, the U.S. Food and Drug Administration approved GSK’s Hibsago for selected adults with chronic hepatitis B virus (HBV) infection. The decision establishes a U.S. treatment option aimed at helping some patients maintain viral control after stopping therapy. (Reuters approval coverage)
Hibsago is administered for up to 24 weeks alongside existing antivirals. Background antiviral therapy continues for at least 24 weeks after the final injection. Only patients meeting the required clinical and laboratory criteria may then discontinue it. The FDA also authorized Roche’s Elecsys HBsAg II quant II RxDx companion diagnostic to support patient selection and monitoring. (FDA approval announcement)
Why It Matters
Existing nucleos(t)ide analogues suppress HBV replication, but sustained loss of hepatitis B surface antigen (HBsAg) remains difficult to achieve. Hibsago targets viral RNA, adding a route toward reducing antigen production.
Across B-Well 1 and B-Well 2, 233 of 1,220 bepirovirsen recipients achieved functional cure, compared with 0 of 614 placebo recipients. Among participants with baseline HBsAg ≤1,000 IU/mL, the response was 26%—200 of 768—versus 0 of 393. This subgroup result strengthens the rationale for patient selection; it does not represent the response of every eligible patient. (GSK approval announcement)
In these trials, functional cure meant HBsAg was undetectable and HBV DNA remained below the specified assay threshold 24 weeks after all HBV treatment stopped. It does not establish elimination of every viral DNA reservoir. (B-Well trial presentation)
The approval therefore advances a previously reported clinical result into a treatment decision: which patients are suitable, and whether the chance of sustained control justifies treatment and monitoring.
Science Brief: How Bepirovirsen Works
Bepirovirsen binds complementary sequences in HBV RNA, including messenger RNA and pregenomic RNA. The resulting RNA–ASO duplex recruits the patient’s own ribonuclease H1 (RNase H1), which cleaves the RNA strand.
RNA degradation reduces the templates available for viral protein production, including HBsAg. Degrading pregenomic RNA also reduces the template used by the viral polymerase to produce HBV DNA through reverse transcription. This RNA-targeting mechanism is described in research involving GSK and Ionis scientists. (Developer-authored mechanism study)
The functional outcome is reduced viral RNA and antigen production, potentially supporting sustained viral control in some patients. Bepirovirsen does not directly remove viral DNA.
Bepirovirsen binds HBV RNA and recruits RNase H1 to promote RNA degradation, reducing viral protein production. Molecular shapes are schematic and do not represent experimentally determined structures.
The Main Risks
Safety monitoring is integral to treatment. Hibsago carries boxed warnings for on-treatment hepatic flares and thrombocytopenia, which can cause life-threatening bleeding. Platelet counts require at least weekly monitoring during treatment, alongside liver laboratory monitoring. Additional warnings include worsening renal function and serious inflammatory reactions. (GSK U.S. safety information)
Most trial participants did not achieve functional cure. The pooled response establishes a meaningful benefit while leaving substantial unmet need.
Commercial adoption will depend on access to testing, specialist capacity, treatment completion and reimbursement. These are practical considerations for a therapy whose benefit must be weighed against repeated injections and close monitoring.
BP View
Hibsago gives GSK an approved route toward finite treatment for a defined group of patients with chronic hepatitis B. The commercial opportunity rests on how effectively that pathway works outside clinical trials.
Early adoption should be assessed through eligible-patient identification, treatment completion, safety management and sustained off-treatment responses. Those measures will show whether the clinical advance translates into a workable option for patients and providers.
If you have questions about the mechanism or a different view on its clinical potential, leave a comment below.
Related Post
Roche’s ALK7 program offers another example of RNA targeting to reduce disease-related protein production. It uses RNA interference, a different platform from bepirovirsen’s ASO approach.
Read my previous analysis: Roche Licenses Rona’s ALK7 RNAi Candidate for Obesity.
About BP
Biopharma Perspective connects clinical evidence, drug mechanisms and industry strategy to explain what biopharma developments could mean in practice.
Leave a Reply